Ribociclib Forestalls Recurrence Also in Early Breast Cancer Ribociclib Forestalls Recurrence Also in Early Breast Cancer
The combination, known to be effective in metastatic disease, has now also been shown to reduce recurrence in earlier-stage disease when used in combination with endocrine therapy.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 2, 2023 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
CDK4/6 Extends Reach Into Early-Stage Breast Cancer
(MedPage Today) -- CHICAGO -- Adding ribociclib (Kisqali) to adjuvant endocrine therapy significantly improved invasive disease-free survival (iDFS) in patients with early-stage, high-risk breast cancer and hormone receptor (HR)-positive/HER2... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - June 2, 2023 Category: Hematology Source Type: news
ASCO Backs Routine ESR1 Testing for Certain Breast Cancers
(MedPage Today) -- American Society of Clinical Oncology (ASCO) clinical practice guidelines now recommend routine testing for the emergence of ESR1 mutations at recurrence or progression on endocrine therapy -- with or without a CDK4/6 inhibitor... (Source: MedPage Today OB/GYN)
Source: MedPage Today OB/GYN - May 18, 2023 Category: OBGYN Source Type: news
Pausing Endocrine Therapy to Attempt Pregnancy Is Safe Pausing Endocrine Therapy to Attempt Pregnancy Is Safe
The POSITIVE trial provides strong evidence that women with HR-positive early breast cancer can safely interrupt endocrine therapy to try to become pregnant.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - May 5, 2023 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
Temporary Interruption of Endocrine Therapy for Breast Cancer Safe
THURSDAY, May 4, 2023 -- Among select women with previous hormone receptor-positive early breast cancer, there is no increase in the short-term risk for breast cancer events with temporary interruption of endocrine therapy to attempt pregnancy,... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - May 4, 2023 Category: Pharmaceuticals Source Type: news
Novartis gets positive result from breast-cancer drug trial
Novartis AG said Monday that a trial evaluating breast-cancer drug Kisqali met its primary endpoint during an interim analysis. The drug is shown to significantly reduce the risk of disease recurrence when used together with an endocrine therapy in patients with certain types of early breast…#novartisag #natalee #novartisnovn #novn (Source: Reuters: Health)
Source: Reuters: Health - March 27, 2023 Category: Consumer Health News Source Type: news
Is AI ready for managing patients with hip fractures?
Artificial intelligence (AI) algorithms can perform comparably to radiologist...Read more on AuntMinnie.comRelated Reading:
Fracture risk tool validated in men with prostate cancer
AI algorithm aids in classifying hip fractures on radiographs
Bone fractures are common after breast cancer endocrine therapy
New CPT code for radiology AI brings hope, but patience is needed
Using AI with x-ray improves hip fracture diagnosis (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - March 17, 2023 Category: Radiology Source Type: news
FDA Expands Indication for Use of Abemaciclib With Early, High-Risk Breast Cancer
FRIDAY, March 10, 2023 -- Abemaciclib (Verzenio) with endocrine therapy (tamoxifen or an aromatase inhibitor) is now approved for the adjuvant treatment of adult patients with hormone receptor-positive, human epidermal growth factor receptor... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - March 10, 2023 Category: Pharmaceuticals Source Type: news
FDA expands early breast cancer indication for abemaciclib with endocrine therapy
On March 3, 2023, the Food and Drug Administration (FDA) approved abemaciclib (Verzenio, Eli Lilly and Company) with endocrine therapy (tamoxifen or an aromatase inhibitor) for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - March 6, 2023 Category: Drugs & Pharmacology Authors: FDA Source Type: news
FDA Broadens Indication for Verzenio (abemaciclib) in HR+, HER2-, Node-Positive, High Risk Early Breast Cancer
INDIANAPOLIS, March 3, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Food and Drug Administration (FDA) approved an expanded indication for Verzenio (abemaciclib), in combination with endocrine therapy (ET),... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - March 3, 2023 Category: Drugs & Pharmacology Source Type: news
Real-World Survival Benefit With CDK4/6 Inhibitors in MBC Real-World Survival Benefit With CDK4/6 Inhibitors in MBC
Registry data confirm an overall survival benefit when a CDK4/6 inhibitor is added to endocrine therapy in HR-positive metastatic breast cancer.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - February 23, 2023 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
Safe to Omit RT After Lumpectomy in Certain Older Breast Cancer Patients
(MedPage Today) -- Radiotherapy after breast-conserving surgery can be safely omitted in certain older women with low-risk, hormone receptor-positive early breast cancer receiving adjuvant endocrine therapy, 10-year results of the PRIME II trial... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - February 15, 2023 Category: Hematology Source Type: news
FDA Approves Orserdu (elacestrant) for Patients with ESR1 Mutations in ER+, HER2- Advanced or Metastatic Breast Cancer
ESR1 mutations are present in up to 40% of ER+, HER2- advanced or metastatic breast cancers.
ESR1 mutations are a known driver of resistance to standard endocrine therapy, and so far, have been difficult to treat.
Orserdu is the first endocrine... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - January 30, 2023 Category: Drugs & Pharmacology Source Type: news
Spine x-rays recommended in prostate cancer patients
Spinal x-rays should be considered to determine the true risk of vertebral fracture...Read more on AuntMinnie.comRelated Reading:
Bone scan capacity increased to meet COVID-19 backlog
AI may aid fracture detection in osteoporotic patients
Bone fractures are common after breast cancer endocrine therapy
AI predicts heart disease risk in DEXA images
AI accurately detects vertebral fractures on CT (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - January 9, 2023 Category: Radiology Source Type: news
Recurrence Score Indicates When to Use Endocrine Therapy Recurrence Score Indicates When to Use Endocrine Therapy
Scores on a breast recurrence assay may signal which patients can get neoadjuvant endocrine therapy vs chemotherapy. The study was published as a preprint and has not yet been peer reviewed.First Look (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - January 5, 2023 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
